PARParadigm Biopharmaceuticals
About Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals (ASX:PAR) is an Australian biotechnology company developing injectable pentosan polysulfate sodium (iPPS) for the treatment of osteoarthritis (OA). OA is a degenerative joint disease that affects millions of people worldwide, and there is currently no cure. Paradigm's operations are focused on the development and commercialisation of iPPS. The company is currently conducting Phase 3 clinical trials of iPPS for the treatment of knee OA, and it expects to submit regulatory applications for approval in 2024. Paradigm is also exploring the use of iPPS to treat other forms of OA, such as hip and shoulder OA.
What is PAR known for?
Snapshot
Public AU
Ownership
2014
Year founded
29
Employees
Victoria, Australia
Head office
1 of 41
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Australia
Produtos e/ou serviços de Paradigm Biopharmaceuticals
- Osteoarthritis: Paradigm Biopharmaceuticals is developing Zilosul® (iPPS) for the treatment of osteoarthritis, with Phase 3 trials underway.
- Respiratory: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to target ARDS based on its multiple mechanisms of action outlined in preclinical studies.
- Lysosomal Storage Diseases: Paradigm Biopharmaceuticals is developing Pentosan Polysulfate Sodium to help manage bone and joint manifestations, chronic pain, and physical disability, key clinical manifestations of MPS I which remain despite treatment with HSCT and ERT.
equipe executiva do Paradigm Biopharmaceuticals
- Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTCFounder, MD & Executive Chairman
- Dr. Donna L. Skerrett M.D., MSChief Medical Officer and Executive Director
- Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A.Interim Company Secretary & Interim CFO
- Dr. Ravi KrishnanChief Scientific Officer
- Mr. Simon WhiteDirector of Investor Relations
- Dr. Michael ImperialeGlobal Head of Drug Safety & MPS
- Ms. Beverley HuttmannCommercial Head
- Ms. Michelle CoffeyGlobal Head of Regulatory Affairs
- Dr. Mukesh AhujaGlobal Clinical Head of OA